Find information on thousands of medical conditions and prescription drugs.

Zevalin

Ibritumomab tiuxetan, also sold under the trade name ZevalinĀ® is a monoclonal antibody radioimmunotherapy treatment for some forms of non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system. This drug uses the parent mouse antibody to Rituxan (another treatment for lymphoma) call tositumomab, and adds it to radioactive isotopes Yttrium (Y-90) or Indium (In-111). The antibody binds to the CD20 antigen found on the surface of B cells, letting radiation from isotope (mostly beta emittion) to kill that cell and some surrounding cells. This eliminates B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Administered by intravenous infusion which usually lasts around 10 minutes. Treatment with Zevalin (which also includes Rituxan) showed higher response rates in clinical trials compared to treatment with only Rituxan, and showed very promising results for patients who no longer respond to Rituxan.

Developed by the IDEC Pharmaceuticals Corporation, which is now part of Biogen Idec, Ibritumomab Tiuxetan was the first radioimmunotherapy drug approved by the FDA in 2002 to treat cancer.

Also see Bexxar, another monoclonal antibody radioimmunotherapy treatment of non-Hodgkin's lymphoma.

Read more at Wikipedia.org


[List your site here Free!]


Ibritumomab Tiuxetan (Zevalin) in Non-Hodgkin's Lymphoma: Clinical Background, Practical Considerations, and Case Studies $9.98 Idec starts shipping new cancer drug; Biotech: Zevalin is first radioimmunotherapy to reach the market. (Tech Talk).(Brief Article)(Statistical Data Included) ... An article from: San Diego Business Journal $5.95
Idec scores big win in patent lawsuit: judge rules that area firm didn't infringe on patent of rival.(News And Finance)(lymphoma drug Zevalin) : An article from: San Diego Business Journal $5.95 Idec to reap huge benefits with drug's approval: Biotech; Zevalin expected to earn hundreds of millions in sales for local company. (Tech Talk).(IDEC Pharmaceuticals ... An article from: San Diego Business Journal $5.95
The Role of Imaging with ^sup 111^In-Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry : An article from: The Journal of Nuclear Medicine $20.00 Idec Gets FDA OK on Cancer Drug.(Zevalin)(Brief Article) : An article from: San Diego Business Journal $5.95
IDEC REPORTS FAVORABLE RESULTS OF FOUR ZEVALIN STUDIES.(Statistical Data Included) : An article from: Biotech Business $5.95

European Commission Approves Zevalin Radioimmunotherapy
Biogen Idec (NASDAQ: BIIB) has announced that the European Commission has granted marketing approval for ZEVALIN(r) (Ibritumomab tiuxetan) radioimmunotherapy.
New Data Demonstrate ZEVALIN® Radioimmunotherapy May Play Greater Role in Combination with Standard of Care for Various Types of Lymphoma
New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play Greater Role in Combination with Standard of Care for Various Types of Lymphoma.
In god we trust, all others show data: a reply to the NCI director's "challenge vision"—Part 2
Predictions of Cure [ILLUSTRATION OMITTED] In a 2004 article, Dr. Andrew C. von Eschenbach, the director of the US National Cancer Institute (NCI) ...
MDS Nordion supplies Yttrium-90 for ZEVALIN, novel radioimmunotherapy for non-Hodgkin's lymphoma
Berlex Canada's ZEVALIN, recently approved for use in Canada, is a proven radioimmunotherapy treatment OTTAWA, Sept. 20 /PRNewswire-FirstCall/ -- ...
Syringe pump
The Graseby Medical 3400 Syringe Pump infuses commonly used nuclear medicine IV drugs such as Aadenosine, Dobutamine, Dipyridamole and Cholecystokinan.
ZEVALIN Therapeutic Regimen Appears Effective in Most Common Type of Lymphoma; New Data at ASH Show Utility of ZEVALIN in Various Lymphoma Subtypes and
SAN DIEGO, Calif. -- Biogen Idec, Inc. (Nasdaq: BIIB) today announced new data on ZEVALIN(R) (ibritumomab tiuxetan) being presented at the 46th Annual ...
New therapeutic approaches to non-Hodgkin's lymphomas
Over the last thirty years, the yearly incidence of non-Hodgkin's lymphomas (NHL) has almost doubled to about 20 new cases per 100,000 people. The cause ...
2002 biotech drug launches
The FDA has approved 20 new biotechnology-based drugs and vaccines as well as 15 new indications for previously approved biotech products in 2002. According to the Biotechnology Industry Organiza

Home Contact Resources Exchange Links ebay